29.10
0.04 (0.14%)
| Previous Close | 29.06 |
| Open | 29.84 |
| Volume | 100,689 |
| Avg. Volume (3M) | 1,063,966 |
| Market Cap | 3,121,572,096 |
| Price / Book | 6.12 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -1.55 |
| Total Debt/Equity (MRQ) | 1.06% |
| Current Ratio (MRQ) | 20.99 |
| Operating Cash Flow (TTM) | -118.30 M |
| Levered Free Cash Flow (TTM) | -67.74 M |
| Return on Assets (TTM) | -21.08% |
| Return on Equity (TTM) | -30.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Edgewise Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -1.00 |
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 104.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Braidwell Lp | 31 Dec 2025 | 5,210,831 |
| 52 Weeks Range | ||
| Median | 45.00 (54.64%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 27 Feb 2026 | 45.00 (54.64%) | Buy | 30.44 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 |
| 02 Feb 2026 | Announcement | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules |
| 13 Jan 2026 | Announcement | Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 |
| 06 Jan 2026 | Announcement | Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 |
| 05 Jan 2026 | Announcement | Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules |
| 24 Dec 2025 | Announcement | Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |